This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Harousseau, J. L.
Right arrow Articles by De Beule, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Harousseau, J. L.
Right arrow Articles by De Beule, K.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, July 2000, p. 1887-1893, Vol. 44, No. 7
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

Itraconazole Oral Solution for Primary Prophylaxis of Fungal Infections in Patients with Hematological Malignancy and Profound Neutropenia: a Randomized, Double-Blind, Double-Placebo, Multicenter Trial Comparing Itraconazole and Amphotericin B

J. L. Harousseau,1 A. W. Dekker,2 A. Stamatoullas-Bastard,3 A. Fassas,4 W. Linkesch,5 J. Gouveia,6 R. De Bock,7 M. Rovira,8 W. F. Seifert,9 H. Joosen,9 M. Peeters,9 and K. De Beule9,*

Hôpital Dieu, Nantes,1 and Centre Henri Becquerel, Rouen,3 France; University Hospital, Utrecht, The Netherlands2; George Papanikolaou General Hospital, Thessalonika, Greece4; Medizinische Universitätsklinik, Graz, Austria5; Hospital Dos Capuchos, Lisbon, Portugal6; Algemeen Ziekenhuis Middelheim, Antwerp,7 and Janssen Research Foundation, Beerse,9 Belgium; and Hospital Clínic IDIBAPS, Barcelona, Spain8

Received 2 December 1999/Returned for modification 9 February 2000/Accepted 24 April 2000

Systemic and superficial fungal infections are a major problem among immunocompromised patients with hematological malignancy. A double-blind, double-placebo, randomized, multicenter trial was performed to compare the efficacy and safety of itraconazole oral solution (2.5 mg/kg of body weight twice a day) with amphotericin B capsules (500 mg orally four times a day) for prophylaxis of systemic and superficial fungal infection. Prophylactic treatment was initiated on the first day of chemotherapy and was continued until the end of the neutropenic period (>0.5 × 109 neutrophils/liter) or up to a maximum of 3 days following the end of neutropenia, unless a systemic fungal infection was documented or suspected. The maximum treatment duration was 56 days. In the intent-to-treat population, invasive aspergillosis was noted in 5 (1.8%) of the 281 patients assigned to itraconazole oral solution and in 9 (3.3%) of the 276 patients assigned to oral amphotericin B; of these, 1 and 4 patients died, respectively. Proven systemic fungal infection (including invasive aspergillosis) occurred in 8 patients (2.8%) who received itraconazole, compared with 13 (4.7%) who received oral amphotericin B. Itraconazole significantly reduced the incidence of superficial fungal infections as compared to oral amphotericin B (2 [1%] versus 13 [5%]; P = 0.004). Although the incidences of suspected fungal infection (including fever of unknown origin) were not different between the groups, fewer patients were administered intravenous systemic antifungals (mainly intravenous amphotericin B) in the group receiving itraconazole than in the group receiving oral amphotericin B (114 [41%] versus 132 [48%]; P = 0.066). Adequate plasma itraconazole levels were achieved in about 80% of the patients from 1 week after the start of treatment. In both groups, the trial medication was safe and well tolerated. Prophylactic administration of itraconazole oral solution significantly reduces superficial fungal infection in patients with hematological malignancies and neutropenia. The incidence of proven systemic fungal infections, the number of deaths due to deep fungal infections, and the use of systemic antifungals tended to be lower in the itraconazole-treated group than in the amphotericin B-treated group, without statistical significance. Itraconazole oral solution is a broad-spectrum systemic antifungal agent with prophylactic activity in neutropenic patients, especially for those at high risk of prolonged neutropenia.

* Corresponding author. Mailing address: Janssen Research Foundation, 2340 Beerse, Belgium. Phone: 32 14 60 34 43. Fax: 32 14 60 29 76. E-mail: kdbeule{at}janbe.jnj.com.

Antimicrobial Agents and Chemotherapy, July 2000, p. 1887-1893, Vol. 44, No. 7
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Cornely, O. A., Bohme, A., Buchheidt, D., Einsele, H., Heinz, W. J., Karthaus, M., Krause, S. W., Kruger, W., Maschmeyer, G., Penack, O., Ritter, J., Ruhnke, M., Sandherr, M., Sieniawski, M., Vehreschild, J.-J., Wolf, H.-H., Ullmann, A. J. (2009). Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology. haematol 94: 113-122 [Abstract] [Full Text]  
  • Masterton, R. G., Galloway, A., French, G., Street, M., Armstrong, J., Brown, E., Cleverley, J., Dilworth, P., Fry, C., Gascoigne, A. D., Knox, A., Nathwani, D., Spencer, R., Wilcox, M. (2008). Guidelines for the management of hospital-acquired pneumonia in the UK: Report of the Working Party on Hospital-Acquired Pneumonia of the British Society for Antimicrobial Chemotherapy. J Antimicrob Chemother 62: 5-34 [Abstract] [Full Text]  
  • Stella, V. J., He, Q. (2008). Cyclodextrins. Toxicol Pathol 36: 30-42 [Abstract] [Full Text]  
  • Robenshtok, E., Gafter-Gvili, A., Goldberg, E., Weinberger, M., Yeshurun, M., Leibovici, L., Paul, M. (2007). Antifungal Prophylaxis in Cancer Patients After Chemotherapy or Hematopoietic Stem-Cell Transplantation: Systematic Review and Meta-Analysis. JCO 25: 5471-5489 [Abstract] [Full Text]  
  • Glasmacher, A., Cornely, O., Ullmann, A. J., Wedding, U., Bodenstein, H., Wandt, H., Boewer, C., Pasold, R., Wolf, H.-H., Hanel, M., Dolken, G., Junghanss, C., Andreesen, R., Bertz, H., on behalf of the Itraconazole Research Group of Ge, (2006). An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia. J Antimicrob Chemother 57: 317-325 [Abstract] [Full Text]  
  • Pfaller, M. A., Boyken, L., Hollis, R. J., Messer, S. A., Tendolkar, S., Diekema, D. J. (2005). In Vitro Susceptibilities of Clinical Isolates of Candida Species, Cryptococcus neoformans, and Aspergillus Species to Itraconazole: Global Survey of 9,359 Isolates Tested by Clinical and Laboratory Standards Institute Broth Microdilution Methods. J. Clin. Microbiol. 43: 3807-3810 [Abstract] [Full Text]  
  • Singh, N., Paterson, D. L. (2005). Aspergillus Infections in Transplant Recipients. Clin. Microbiol. Rev. 18: 44-69 [Abstract] [Full Text]  
  • Johnson, M. D., MacDougall, C., Ostrosky-Zeichner, L., Perfect, J. R., Rex, J. H. (2004). Combination Antifungal Therapy. Antimicrob. Agents Chemother. 48: 693-715 [Full Text]  
  • Marr, K. A., Crippa, F., Leisenring, W., Hoyle, M., Boeckh, M., Balajee, S. A., Nichols, W. G., Musher, B., Corey, L. (2004). Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood 103: 1527-1533 [Abstract] [Full Text]  
  • de Pauw, B. (2004). Preventative use of antifungal drugs in patients treated for cancer. J Antimicrob Chemother 53: 130-132 [Abstract] [Full Text]  
  • Glasmacher, A., Prentice, A., Gorschluter, M., Engelhart, S., Hahn, C., Djulbegovic, B., Schmidt-Wolf, I. G.H. (2003). Itraconazole Prevents Invasive Fungal Infections in Neutropenic Patients Treated for Hematologic Malignancies: Evidence From a Meta-Analysis of 3,597 Patients. JCO 21: 4615-4626 [Abstract] [Full Text]  
  • Winston, D. J., Maziarz, R. T., Chandrasekar, P. H., Lazarus, H. M., Goldman, M., Blumer, J. L., Leitz, G. J., Territo, M. C. (2003). Intravenous and Oral Itraconazole versus Intravenous and Oral Fluconazole for Long-Term Antifungal Prophylaxis in Allogeneic Hematopoietic Stem-Cell Transplant Recipients: A Multicenter, Randomized Trial. ANN INTERN MED 138: 705-713 [Abstract] [Full Text]  
  • Cornely, O. A., Ullmann, A. J., Karthaus, M. (2003). Evidence-based assessment of primary antifungal prophylaxis in patients with hematologic malignancies. Blood 101: 3365-3372 [Abstract] [Full Text]  
  • Pandya, N A, Atra, A A, Riley, U, Pinkerton, C R (2003). Role of itraconazole in haematology/oncology. Arch. Dis. Child. 88: 258-260 [Abstract] [Full Text]  
  • Johnson, M. D., Hamilton, C. D., Drew, R. H., Sanders, L. L., Pennick, G. J., Perfect, J. R. (2003). A randomized comparative study to determine the effect of omeprazole on the peak serum concentration of itraconazole oral solution. J Antimicrob Chemother 51: 453-457 [Abstract] [Full Text]  
  • Lewis, R. E., Prince, R. A., Chi, J., Kontoyiannis, D. P. (2002). Itraconazole Preexposure Attenuates the Efficacy of Subsequent Amphotericin B Therapy in a Murine Model of Acute Invasive Pulmonary Aspergillosis. Antimicrob. Agents Chemother. 46: 3208-3214 [Abstract] [Full Text]  
  • Somchit, N, Hassim, S M, Samsudin, S H (2002). Itraconazole and fluconazole-induced toxicity in rat hepatocytes: a comparativein vitro study. Hum Exp Toxicol 21: 43-48 [Abstract]  
  • Boogaerts, M., Maertens, J., van Hoof, A., de Bock, R., Fillet, G., Peetermans, M., Selleslag, D., Vandercam, B., Vandewoude, K., Zachee, P., De Beule, K. (2001). Itraconazole versus amphotericin B plus nystatin in the prophylaxis of fungal infections in neutropenic cancer patients. J Antimicrob Chemother 48: 97-103 [Abstract] [Full Text]  
  • De Backer, M. D., Ilyina, T., Ma, X.-J., Vandoninck, S., Luyten, W. H. M. L., Vanden Bossche, H. (2001). Genomic Profiling of the Response of Candida albicans to Itraconazole Treatment Using a DNA Microarray. Antimicrob. Agents Chemother. 45: 1660-1670 [Abstract] [Full Text]  
  • Reichenberger, F., Habicht, J.M., Gratwohl, A., Tamm, M. (2001). Diagnosis and treatment of invasive pulmonary aspergillosis in neutropenic patients. Eur Respir J 19: 743-755 [Abstract] [Full Text]  
  • Kontoyiannis, D. P., Lewis, R. E., Sagar, N., May, G., Prince, R. A., Rolston, K. V. I. (2000). Itraconazole-Amphotericin B Antagonism in Aspergillus fumigatus: an E-Test-Based Strategy. Antimicrob. Agents Chemother. 44: 2915-2918 [Abstract] [Full Text]  
  • (2000). Itraconazole or Amphotericin B to Prevent Fungal Infections in Neutropenic Patients?. JWatch Infect. Diseases 2000: 6-6 [Full Text]  


Copyright © 2010 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»